Therefore, the targeting of BCL-xL and BCL-2 with small molecule inhibitors has been explored as a therapeutic strategy in SCLC, since the discovery of navitoclax [1,16,17,18,19,20,21]. Here, BCL2 is linked to small cell lung carcinoma.